CBGa, or cannabigerolic acid, is one of the cannabinoids least present in Cannabis plants. Providing a protective function for cannabis, CBGa is produced in the trichomes of the plant and triggers targeted necrosis of the plant cells to naturally regulate leaf size to allow the plant to maximize energy directed to the flower.
CBGa is also a founding component of the cannabis flower. It occurs at the very beginning of the chain reaction that produces the three main cannabinoids:
THC (tetrahydrocannabinolic acid)
CBDa (cannabidiolic acid)
CBN (cannabinol acid)
The latter then evolve into THC, CBD, and CBN respectively. CaGBC is also transformed into CBG, but most of the time directly into THC and CBD.
Although it has been known for 30 years, with Japanese researchers revealing its role as a precursor in 1996, CaGBC has received little study. Scientists have further studied THCa, and how CBGa is converted to THCa.
The medical potential of CaGBC
With little research to its credit, CaGBC has nevertheless shown potential therapeutic applications, which will still require some further studies. For the time being, the best way to enjoy CBGa remains hemp juice from a highly dosed variety.
CaGBC may be effective for colorectal cancer patients. The researchers examined the cytotoxic effects of CBGa extracted from cannabis and found that CBGa not only destroyed colon cancer cells but also accelerated the early death of cancer cells and stopped the cycle of cancer cells. Although further research is necessary, the researchers believe that CaGBC could effectively target not only colon cancer cells, but also prevent the growth and proliferation of polyps. Untreated, these polyps turn into carcinomas.
CaGBC could help diabetic patients fight some of the complications of the disease and comorbidities such as cardiovascular disease. CaGBC has been studied in vitro and has been shown to inhibit the enzyme aldose reductase, a major contributor to oxidative stress that causes heart and other problems. The test results were highly dosing dependent. Drugs based on synthetic inhibitors have strong side effects for many patients. A drug derived from plants and with CBGa would, therefore, be promising.
CaGBC could also help patients with metabolic disorders. 2019 in silico study (a computer simulation in fact) examined the role of CBGa in activating receptors activated by peroxisome proliferators (PPARs) that regulate metabolism. When PPARs do not work properly, people develop diseases such as diabetes and high levels of cholesterol or triglycerides (dyslipidemia). This study showed that CaGBC activates PPAR receptors, thereby stimulating lipid metabolism and reducing the accumulation of excess lipids. The study should be continued on living models.